Sign In
5 Jan 2010 07:00
|
For immediate release |
5 January 2010 |
TYRATECH, INC.
("TyraTech" or "the Company")
Board Changes
The Board of TyraTech, Inc. (AIM: TYR) a leading independent novel eco-technology company for human, animal and environmental health, announces that Dr Douglas Armstrong has stepped down as Chief Executive Officer and has resigned as a director of the Company. Alan Reade, currently a Non-executive Director who has been on the Board of TyraTech since the Company's AIM flotation in 2007, has assumed the role of Executive Chairman and will take charge of the day to day affairs of the Company.
Alan Reade's career spans over thirty years within the life sciences industry. From 2000 until his retirement in 2005, he served as executive chairman of Merial Limited, a leading animal health company and joint venture between Merck & Co. Inc. and Sanofi- Aventis. Earlier in his career he was head of global integration at Aventis, where he was in charge of merger integration, and Chief Executive Officer and member of the Global Management Board of Rhone-Poulenc Agrochimie.
Geoffrey Vernon, currently Non-executive Chairman assumes the role of Non-Executive Director.
All Officer and Board changes are with immediate effect.
Geoffrey Vernon, Non-Executive Director commented:
"On behalf of the Board, I would like to thank Doug for his contribution to the development of TyraTech since the Company's Admission to AIM in 2007 and we wish him every success in his future endeavours. Similarly the Board would like to thank Alan for stepping into the Executive Chairman's position. Alan has a wealth of experience within the industry particularly in animal health and through his more active executive role will be invaluable to the continued smooth running of the business."
- Ends -
For further information please contact:
TyraTech Inc.
Geoffrey Vernon, Non-Executive director +44 (0)20 7466 5000
www.tyratech.com
Nomura Code Securities
Clare Terlouw / Chris Golden +44 (0)20 7776 1200
www.nomuracode.com
Buchanan Communications
Lisa Baderoon/ Catherine Breen / Stasa Filiplic +44 (0)20 7466 5000
www.buchanan.uk.com
Follow the stocks
